Ionis Announces European Medicines Agency Accepts Marketing Authorization Application for Tofersen to Treat Rare Genetic Form of ALS
SOD1-ALS affects approximately 2% of people living with ALS worldwide1 If approved, tofersen would be the world’s first treatment to target a genetic cause of ALS EMA acceptance follows FDA acceptance of tofersen NDA earlier this year CARLSBAD, Calif., December 5, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the European Medicines …
